Many tissue-based biomarker assays are currently in use to estimate the response to immunotherapy, including PD-L1 immunohistochemistry (IHC), tumor mutational burden, gene expression profiling, and multiplex IHC/immunofluorescence. This evidence concerns the gene CD274 and neoplasm.